The Clinical and Laboratory Features of Kawasaki Disease with Nonresponsibility to the Acute Antiinflammatory Treatment.
- Author:
Eun Jung KIM
1
;
Myung Eun HONG
;
Chang Woo LEE
;
Yeon Geun OH
;
Jong Duk KIM
Author Information
1. Department of Pediatrics, School of Medicine, Wonkwang University, Iksan, Korea. yhs0520@wonkwang.ac.kr
- Publication Type:Original Article
- Keywords:
Kawasaki disease;
Retreatment;
AST/ALT;
ASO
- MeSH:
Academic Medical Centers;
Aspirin;
Humans;
Medical Records;
Mucocutaneous Lymph Node Syndrome*;
Pyuria;
Retreatment;
Retrospective Studies;
Risk Factors
- From:Journal of the Korean Pediatric Society
2003;46(5):500-504
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: To assess the clinical features and laboratory findings in Kawasaki patients with nonresponsibility to the acute antiinflammatory treatment, and identify the risk factors for the nonresponsibility, we reviewed the medical records of patients with Kawasaki disease. METHODS: A retrospective study of 177 patients with Kawasaki disease at Wonkwang University Medical Center from June, 1997 to June, 2002, was performed. High dose intravenous immune globulin(IVIG) and aspirin were all used for the initial acute antiinflammatory treatment. Two groups, group A(n=19) of initial nonresponders and group B(n=158) of initial responders were compared clinically and laboratorically. RESULTS: Nineteen(10.7%) of 177 patients hardly responded to the initial antiinflammatory treatment. Patients with failure to respond to initial treatment(group A) did not differ from the control group in terms of age, sex, WBC count, coronary abnormalities, and evidence of pyuria. Compared with initial responders(group B), the patients who were retreated(group A) had a significantly shorter fever- admission interval(P=0.041), and a higher level of both AST/ALT(P=0.011) and ASO titier(P=0.000). CONCLUSION: Among Kawasaki disease patients studied, retreatment group with initial nonresponders had significantly shorter fever-admission interval, and higher both AST/ALT level and ASO titer, than the initial response group.
